Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm specializing in life sciences, with a focus on healthcare and sustainability. Founded in 1972 and based in Paris, London, and Milan, it manages over €4 billion in assets and has backed more than 500 companies.
AUM
€4.0B
Funds
13
vintages 2008–2025
Portfolio
108
Exits
37
SectorsHealthcareIndustrials
Key facts
Recent exits
PinCell
Biotech · 2025 · 6yr hold
Sphere Bio (formerly Sphere Fluidics)
MedTech · 2025 · 4yr hold
Verona Pharma
Biotech · 2025 · 6yr hold
Betteromics
HealthTech · 2024 · 2yr hold
Coverage notes
13 funds tracked, 145 portfolio companies (108 active · 37 realized). Verified weekly from public filings and deal announcements.
Funds & portfolio
Every fund Sofinnova Partners has raised, with its portfolio companies. Hand-checked from public filings.
13 funds
Sofinnova Capital XILife Sciences VC2025 · 1yr€650M2 active
Unrealized
2 held| Company | Sector | Geo | Entry |
|---|---|---|---|
| Actithera | Biotech | France | 2025 |
| BIONYRA PHARMA | Healthcare | France | 2025 |
ActitheraActive
BiotechFrance· Entry 2025
BIONYRA PHARMAActive
HealthcareFrance· Entry 2025
Sofinnova Biovelocita IILife Sciences VC2025 · 1yr€100M1 active
Unrealized
1 held| Company | Sector | Geo | Entry |
|---|---|---|---|
| Signadori Bio | Biotech | Italy | 2025 |
Signadori BioActive
BiotechItaly· Entry 2025
Sofinnova Digital Medicine IVC2022 · 4yr€100M9 active · 1 realized
Unrealized
9 held| Company | Sector | Geo | Entry |
|---|---|---|---|
| BioCorteX | HealthTech | UK | 2022 |
| Bioptimus | Biotech | France | 2024 |
| Cure51 | HealthTech | France | 2024 |
| deepc | HealthTech | Germany | 2021 |
| Excelsior Sciences | HealthTech | US | 2025 |
| Ingenix | AI/ML | Poland | 2026 |
| Kiro | HealthTech | France | 2023 |
| L'école AI | HealthTech | Canada | 2023 |
| Latent Labs | HealthTech | UK | 2025 |
BioCorteXActive
HealthTechUK· Entry 2022
BioptimusActive
BiotechFrance· Entry 2024
Cure51Active
HealthTechFrance· Entry 2024
deepcActive
HealthTechGermany· Entry 2021
Excelsior SciencesActive
HealthTechUS· Entry 2025
IngenixActive
AI/MLPoland· Entry 2026
KiroActive
HealthTechFrance· Entry 2023
L'école AIActive
HealthTechCanada· Entry 2023
Latent LabsActive
HealthTechUK· Entry 2025
Sofinnova Biovelocita ILife Sciences VC2022 · 4yr€50M2 active
Unrealized
2 held| Company | Sector | Geo | Entry |
|---|---|---|---|
| BioClec | Biotech | Italy | 2023 |
| Forth Therapeutics | Biotech | Italy | 2023 |
BioClecActive
BiotechItaly· Entry 2023
Forth TherapeuticsActive
BiotechItaly· Entry 2023
Sofinnova Capital XLife Sciences VC2021 · 5yr€472M27 active · 1 realized
Unrealized
27 held| Company | Sector | Geo | Entry |
|---|---|---|---|
| Catamaran Bio | Biotech | US | 2022 |
| DISCO Pharmaceuticals | Biotech | Germany | 2023 |
| Elevara Medicines | Biotech | UK | 2022 |
| Enthera Pharmaceuticals | Biotech | Italy | 2022 |
| Freya Biosciences | Biotech | Denmark | 2023 |
| Galvanize | MedTech | US | 2022 |
| GlycoEra | Biotech | Switzerland | 2021 |
| Haya Therapeutics | Biotech | Switzerland | 2021 |
| Home Biosciences | Biotech | France | 2022 |
| Inspirna | Biotech | US | 2021 |
| May Health | MedTech | France | 2023 |
| Mediar Therapeutics | Biotech | US | 2021 |
| Mironid | Biotech | UK | 2021 |
| Mnemo Therapeutics | Biotech | France | 2021 |
| Mozart Therapeutics | Biotech | US | 2021 |
| Muna Therapeutics | Biotech | Denmark | 2021 |
| Myricx Bio | Biotech | UK | 2022 |
| NanoPhoria | Biotech | Italy | 2022 |
| Neurent Medical | MedTech | Ireland | 2021 |
| NodThera | Biotech | UK | 2021 |
| Nuage Therapeutics | Biotech | Spain | 2023 |
| Purespring | Biotech | UK | 2021 |
| Redona Therapeutics | Biotech | UK | 2022 |
| Sitryx Therapeutics | Biotech | UK | 2021 |
| T-Therapeutics | Biotech | UK | 2023 |
| Tenpoint Therapeutics | Biotech | US | 2022 |
| Werewool | Biotech | US | 2022 |
Catamaran BioActive
BiotechUS· Entry 2022
DISCO PharmaceuticalsActive
BiotechGermany· Entry 2023
Elevara MedicinesActive
BiotechUK· Entry 2022
Enthera PharmaceuticalsActive
BiotechItaly· Entry 2022
Freya BiosciencesActive
BiotechDenmark· Entry 2023
GalvanizeActive
MedTechUS· Entry 2022
GlycoEraActive
BiotechSwitzerland· Entry 2021
Haya TherapeuticsActive
BiotechSwitzerland· Entry 2021
Home BiosciencesActive
BiotechFrance· Entry 2022
InspirnaActive
BiotechUS· Entry 2021
May HealthActive
MedTechFrance· Entry 2023
Mediar TherapeuticsActive
BiotechUS· Entry 2021
MironidActive
BiotechUK· Entry 2021
Mnemo TherapeuticsActive
BiotechFrance· Entry 2021
Mozart TherapeuticsActive
BiotechUS· Entry 2021
Muna TherapeuticsActive
BiotechDenmark· Entry 2021
Myricx BioActive
BiotechUK· Entry 2022
NanoPhoriaActive
BiotechItaly· Entry 2022
Neurent MedicalActive
MedTechIreland· Entry 2021
NodTheraActive
BiotechUK· Entry 2021
Nuage TherapeuticsActive
BiotechSpain· Entry 2023
PurespringActive
BiotechUK· Entry 2021
Redona TherapeuticsActive
BiotechUK· Entry 2022
Sitryx TherapeuticsActive
BiotechUK· Entry 2021
T-TherapeuticsActive
BiotechUK· Entry 2023
Tenpoint TherapeuticsActive
BiotechUS· Entry 2022
WerewoolActive
BiotechUS· Entry 2022
Realized
1 exit| Company | Sector | Geo | Entry | Exit | Type | Buyer | MOIC |
|---|---|---|---|---|---|---|---|
| Mablink Bioscience | Biotech | France | 2022 | 2023 | Trade Sale | – |
Sofinnova Industrial BiotechVC2018 · 8yr€200M20 active · 2 realized
Unrealized
20 held| Company | Sector | Geo | Entry |
|---|---|---|---|
| Afyren | Biotech | France | 2019 |
| Arzeda | Biotech | US | 2022 |
| Biosyntia | Biotech | Denmark | 2018 |
| Biotalys | Biotech | Belgium | 2019 |
| CelluComp | Biotech | UK | 2015 |
| DMC Biotechnologies | Biotech | US | 2019 |
| DNA Script | Biotech | France | 2017 |
| Elicit Plant | Biotech | France | 2019 |
| EnginZyme | Biotech | Sweden | 2019 |
| ENOBRAQ | Business Services | France | 2019 |
| GFBiochemicals | Biotech | France | 2016 |
| Meiogenix | Biotech | France | 2019 |
| MetGen | Biotech | Finland | 2017 |
| Micropep Technologies | Biotech | France | 2019 |
| Microphyt | Biotech | France | 2019 |
| Novameat | Biotech | Spain | 2021 |
| Prometheus Materials | Biotech | US | 2022 |
| Protera | Biotech | US | 2020 |
| Qorium | Biotech | Netherlands | 2021 |
| Verley (formerly Bon Vivant) | Biotech | France | 2021 |
AfyrenActive
BiotechFrance· Entry 2019
ArzedaActive
BiotechUS· Entry 2022
BiosyntiaActive
BiotechDenmark· Entry 2018
BiotalysActive
BiotechBelgium· Entry 2019
CelluCompActive
BiotechUK· Entry 2015
DMC BiotechnologiesActive
BiotechUS· Entry 2019
DNA ScriptActive
BiotechFrance· Entry 2017
Elicit PlantActive
BiotechFrance· Entry 2019
EnginZymeActive
BiotechSweden· Entry 2019
ENOBRAQActive
Business ServicesFrance· Entry 2019
GFBiochemicalsActive
BiotechFrance· Entry 2016
MeiogenixActive
BiotechFrance· Entry 2019
MetGenActive
BiotechFinland· Entry 2017
Micropep TechnologiesActive
BiotechFrance· Entry 2019
MicrophytActive
BiotechFrance· Entry 2019
NovameatActive
BiotechSpain· Entry 2021
Prometheus MaterialsActive
BiotechUS· Entry 2022
ProteraActive
BiotechUS· Entry 2020
QoriumActive
BiotechNetherlands· Entry 2021
BiotechFrance· Entry 2021
Realized
2 exits| Company | Sector | Geo | Entry | Exit | Type | Buyer | MOIC |
|---|---|---|---|---|---|---|---|
| Avantium | Biotech | Netherlands | 2016 | 2017 | IPO | – | – |
| IB WORKS I | Software | France | 2022 | 2024 | – | – | – |
IB WORKS IExited 2024
SoftwareFrance· Entry 2022
Sofinnova Capital IXLife Sciences VC2018 · 8yr€333M21 active · 4 realized
Unrealized
21 held| Company | Sector | Geo | Entry |
|---|---|---|---|
| Asceneuron | Biotech | Switzerland | 2020 |
| Comet Biorefining | Biotech | Canada | 2019 |
| CorVent Medical | MedTech | US | 2020 |
| CorWave | MedTech | France | 2019 |
| Crescendo Biologics | Biotech | UK | 2018 |
| Genespire | Biotech | Italy | 2020 |
| Hookipa Pharma | Biotech | Austria | 2019 |
| HotSpot Therapeutics | Biotech | US | 2019 |
| Inotrem | Biotech | France | 2019 |
| iOmx Therapeutics | Biotech | Germany | 2018 |
| Mainstay Medical | MedTech | Ireland | 2018 |
| Mission Therapeutics | Biotech | UK | 2019 |
| Moon Surgical | MedTech | France | 2019 |
| Nitrase Therapeutics | Biotech | US | 2020 |
| Pi-Cardia | MedTech | Israel | 2020 |
| ProQR Therapeutics | Biotech | Netherlands | 2018 |
| Pyrowave | Biotech | Canada | 2020 |
| Quince Therapeutics (formerly EryDel) | Biotech | US | 2019 |
| RefleXion Medical | MedTech | US | 2019 |
| SafeHeal | MedTech | France | 2019 |
| Tissium | MedTech | France | 2018 |
AsceneuronActive
BiotechSwitzerland· Entry 2020
Comet BiorefiningActive
BiotechCanada· Entry 2019
CorVent MedicalActive
MedTechUS· Entry 2020
CorWaveActive
MedTechFrance· Entry 2019
Crescendo BiologicsActive
BiotechUK· Entry 2018
GenespireActive
BiotechItaly· Entry 2020
Hookipa PharmaActive
BiotechAustria· Entry 2019
HotSpot TherapeuticsActive
BiotechUS· Entry 2019
InotremActive
BiotechFrance· Entry 2019
iOmx TherapeuticsActive
BiotechGermany· Entry 2018
Mainstay MedicalActive
MedTechIreland· Entry 2018
Mission TherapeuticsActive
BiotechUK· Entry 2019
Moon SurgicalActive
MedTechFrance· Entry 2019
Nitrase TherapeuticsActive
BiotechUS· Entry 2020
Pi-CardiaActive
MedTechIsrael· Entry 2020
ProQR TherapeuticsActive
BiotechNetherlands· Entry 2018
PyrowaveActive
BiotechCanada· Entry 2020
BiotechUS· Entry 2019
RefleXion MedicalActive
MedTechUS· Entry 2019
SafeHealActive
MedTechFrance· Entry 2019
TissiumActive
MedTechFrance· Entry 2018
Realized
4 exits| Company | Sector | Geo | Entry | Exit | Type | Buyer | MOIC |
|---|---|---|---|---|---|---|---|
| CinCor Pharma | Biotech | US | 2019 | 2023 | Trade Sale | – | |
| Noema Pharma | Biotech | Switzerland | 2020 | 2022 | – | – | |
| PinCell | Biotech | Italy | 2019 | 2025 | Trade Sale | – | |
| Shockwave Medical | MedTech | US | 2018 | 2024 | Trade Sale | – |
Sofinnova Crossover Fund IVC2018 · 8yr€549M10 active · 4 realized
Unrealized
10 held| Company | Sector | Geo | Entry |
|---|---|---|---|
| Abivax | Biotech | France | 2018 |
| Artios Pharma | Biotech | UK | 2020 |
| F2G | Biotech | UK | 2019 |
| GenSight Biologics | Biotech | France | – |
| Hemab Therapeutics | Biotech | Denmark | 2020 |
| Inventiva | Biotech | France | 2019 |
| MaxCyte | Biotech | US | 2019 |
| Redx Pharma | Biotech | UK | 2019 |
| Sensorion | Biotech | France | 2018 |
| Synthace | Biotech | UK | 2019 |
AbivaxActive
BiotechFrance· Entry 2018
Artios PharmaActive
BiotechUK· Entry 2020
F2GActive
BiotechUK· Entry 2019
GenSight BiologicsActive
BiotechFrance
Hemab TherapeuticsActive
BiotechDenmark· Entry 2020
InventivaActive
BiotechFrance· Entry 2019
MaxCyteActive
BiotechUS· Entry 2019
Redx PharmaActive
BiotechUK· Entry 2019
SensorionActive
BiotechFrance· Entry 2018
SynthaceActive
BiotechUK· Entry 2019
Realized
4 exits| Company | Sector | Geo | Entry | Exit | Type | Buyer | MOIC |
|---|---|---|---|---|---|---|---|
| Amolyt Pharma | Biotech | France | 2021 | 2024 | Trade Sale | – | |
| Calliditas | Biotech | Sweden | 2020 | 2024 | Trade Sale | – | |
| Sphere Bio (formerly Sphere Fluidics) | MedTech | United Kingdom | 2021 | 2025 | Trade Sale | – | |
| Verona Pharma | Biotech | UK | 2019 | 2025 | Trade Sale | – |
Sofinnova TelethonLife Sciences VC2016 · 10yr€50M5 active
Unrealized
5 held| Company | Sector | Geo | Entry |
|---|---|---|---|
| AAVantgarde Bio | Biotech | Italy | 2020 |
| Alia Therapeutics | Biotech | Italy | 2021 |
| Borea Therapeutics | Biotech | Italy | 2021 |
| nChroma (formerly Chroma Medicine) | Biotech | US | 2022 |
| Nephris | Biotech | Italy | 2022 |
AAVantgarde BioActive
BiotechItaly· Entry 2020
Alia TherapeuticsActive
BiotechItaly· Entry 2021
Borea TherapeuticsActive
BiotechItaly· Entry 2021
BiotechUS· Entry 2022
NephrisActive
BiotechItaly· Entry 2022
Sofinnova Capital VIIILife Sciences VC2015 · 11yr€300M4 active · 7 realized
Unrealized
4 held| Company | Sector | Geo | Entry |
|---|---|---|---|
| BiovelocITA | Biotech | Italy | 2015 |
| ENYO Pharma | Biotech | France | 2016 |
| HighLife | MedTech | France | 2015 |
| NuCana | Biotech | UK | 2015 |
BiovelocITAActive
BiotechItaly· Entry 2015
ENYO PharmaActive
BiotechFrance· Entry 2016
HighLifeActive
MedTechFrance· Entry 2015
NuCanaActive
BiotechUK· Entry 2015
Realized
7 exits| Company | Sector | Geo | Entry | Exit | Type | Buyer | MOIC |
|---|---|---|---|---|---|---|---|
| Breath Therapeutics | Biotech | Germany | 2016 | 2019 | Trade Sale | – | |
| Corvidia Therapeutics | Biotech | US | 2016 | 2020 | Trade Sale | – | |
| Delinia | Biotech | UK | 2016 | 2017 | Trade Sale | – | |
| Lysogene | Biotech | France | 2015 | 2018 | – | – | – |
| ObsEva | Biotech | Switzerland | 2015 | 2017 | IPO | – | – |
| ReCor Medical | MedTech | US | 2016 | 2018 | Trade Sale | – | |
| VectivBio | Biotech | Switzerland | 2017 | 2023 | Trade Sale | – |
LysogeneExited 2018
BiotechFrance· Entry 2015
Sofinnova Capital VIILife Sciences VC2012 · 14yr€240M1 active · 4 realized
Unrealized
1 held| Company | Sector | Geo | Entry |
|---|---|---|---|
| Pixium Vision | MedTech | France | 2013 |
Pixium VisionActive
MedTechFrance· Entry 2013
Realized
4 exits| Company | Sector | Geo | Entry | Exit | Type | Buyer | MOIC |
|---|---|---|---|---|---|---|---|
| Advanced Perfusion Diagnostics | MedTech | France | 2012 | 2018 | – | – | – |
| Ascendis Pharma | Biotech | Denmark | 2012 | 2015 | IPO | – | – |
| EOS | Biotech | Italy | 2012 | 2013 | Trade Sale | – | |
| GlycoVaxyn | Biotech | Switzerland | 2012 | 2015 | Trade Sale | – |
Advanced Perfusion DiagnosticsExited 2018
MedTechFrance· Entry 2012
Sofinnova MD StartVC2010 · 16yr€30M6 active · 2 realized
Unrealized
6 held| Company | Sector | Geo | Entry |
|---|---|---|---|
| BrightHeart | MedTech | France | 2022 |
| Endoron Medical | MedTech | France | 2021 |
| Gradient Denervation Technologies | MedTech | US | 2023 |
| HEPTA Medical | MedTech | France | 2022 |
| Julier Medical | MedTech | France | 2023 |
| Tulyp Medical | MedTech | France | 2022 |
BrightHeartActive
MedTechFrance· Entry 2022
Endoron MedicalActive
MedTechFrance· Entry 2021
MedTechUS· Entry 2023
HEPTA MedicalActive
MedTechFrance· Entry 2022
Julier MedicalActive
MedTechFrance· Entry 2023
Tulyp MedicalActive
MedTechFrance· Entry 2022
Sofinnova Capital VILife Sciences VC2008 · 18yr€260M0 active · 12 realized
Realized
12 exits| Company | Sector | Geo | Entry | Exit | Type | Buyer | MOIC |
|---|---|---|---|---|---|---|---|
| ABIONYX Pharma | Biotech | France | 2010 | 2020 | IPO | – | – |
| Ablynx NV | Biotech | Belgium | 2008 | 2018 | Trade Sale | – | |
| Addex Therapeutics | Biotech | Switzerland | 2008 | 2012 | – | – | – |
| CoreValve | MedTech | France | 2007 | 2009 | Trade Sale | – | |
| DBV | Biotech | France | 2010 | 2014 | IPO | – | – |
| Genset | Biotech | France | 1989 | 2002 | Trade Sale | – | |
| Innate Pharma | Biotech | France | 2000 | 2006 | IPO | – | – |
| Movetis | Biotech | Belgium | 2008 | 2010 | Trade Sale | – | |
| Novexel | Biotech | France | 2006 | 2010 | Trade Sale | – | |
| Noxxon Pharma | Biotech | Germany | 2008 | 2016 | IPO | – | – |
| Omthera Pharmaceuticals | Biotech | US | 2010 | 2013 | Trade Sale | – | |
| PregLem | Biotech | Switzerland | 2006 | 2010 | Trade Sale | – |
Addex TherapeuticsExited 2012
BiotechSwitzerland· Entry 2008
Track Sofinnova Partners
Saved GPs appear in your watchlist, one click from your workspace.
About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm specialised in life sciences with €4.0 billion of assets under management as of December 2024, headquartered in Paris with additional offices in London and Milan. Founded in 1972, the firm has backed more than 600 life sciences companies over a 53-year track record across multiple biotech, MedTech and HealthTech cycles. Sofinnova focuses exclusively on healthcare and sustainability themes, distinguishing the platform from generalist VC firms.
Investment thesis
Sofinnova deploys capital across complementary life sciences strategies including Biotech (drug discovery and development), MedTech (medical devices and digital health), HealthTech (digital health platforms) and selective Industrial Biotech and Sustainability themes. Investment stages span early-stage seed and Series A through growth equity and pre-IPO commitments, with equity tickets typically ranging from €5 million to €50 million per transaction. The platform's sector-exclusive focus enables deep scientific and clinical expertise across translational research, regulatory navigation and commercial scale-up.
Recent activity
Recent realised exits include PinCell (biotech, 2025), Verona Pharma (biotech, 2025), Amolyt Pharma (biotech, 2024), Betteromics (HealthTech, 2024) and Calliditas (biotech, 2024), reflecting strong distribution momentum across the biotech franchise. The platform tracks 13 funds, 107 active portfolio companies and 36 realised exits across a multi-decade track record. Detailed buyer names and multiple data available on Pro at €29/month.
Similar firms
Other private equity firms tracked on GP Intel.
Ardian
France·€196.0BTikehau Capital
France·€52.8BPAI Partners
France·€33.0BLFPI GESTION
France·€27.0BSWEN CAPITAL PARTNERS
France·€13.2BNextStage AM
France·€11.6BARCHIMED
France·€9.0BEiffel Investment Group
France·€7.0BOmnes Capital
France·€6.7BEdmond de Rothschild Private Equity (France)
France·€4.3BCrédit Mutuel Equity
France·€4.0BISALT
France·€3.0BLast updated June 2026 · Sourced from public filings